Oxygen Biotherapeutics develops gel version of Oxycyte for treating surface wounds

Oxygen Biotherapeutics, Inc. has announced that the company has developed a gel-like form of Oxycyte that it intends to investigate as a topical application for open wounds, abrasions and burns. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

The innovation is based on technologies in-licensed earlier this year from Virginia Commonwealth University. In combination with a hydrogen peroxide pouch, researchers believe the compound could have superior abilities to deliver a high concentration of oxygen directly to the wounded tissue. The combination of Oxycyte gel and H2O2 is believed to be the key to its possible efficacy. The company intends to submit to the FDA a protocol for a proposed clinical investigation before the end of the calendar year.

“Unlike the intravenous drug application of Oxycyte in traumatic brain injury, this would be a topical application, applied to the skin or to the surface of wounds. So we’re hopeful that the clinical review process would be as a medical device, which can be shorter and faster than review as a drug,” said company chairman and CEO Chris J. Stern, DBA. “If the safety/efficacy cycle is indeed shorter, as I believe it can be, then it suggests that substantive partnering models could be launched shortly after safety and efficacy are proven. Sales of ointments, dressings, bandages, etc are counted in the high billions of dollars each year. I think that every one of these products could prove to be a candidate to carry a form of Oxycyte.

“While I’m excited about this new potential use for Oxycyte, I know that the big question on our shareholders’ minds right now is the status of our Phase IIb protocol for Oxycyte in TBI. We’re not going to get into the details of our communications with the FDA. That would not be in the best interests of the company or the process. I’ll just say that positive communications are continuing and that when there is news, we’ll announce it,” said Stern.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study suggests beta-blockers may elevate depression symptoms in post-MI patients